Ccn5 Gene Therapy Reduces Myocardial Infarction Size and Improves Contractility in Ischemic Cardiomyopathy
- Authors
- Jeong, Dongtak; Yoo, Jimeen; Song, Min Ho; Gubara, Sarah M.; Katz, Michael G.; Park, Woo Jin; Fargnoli, Anthony
- Issue Date
- Nov-2019
- Publisher
- Lippincott Williams & Wilkins Ltd.
- Citation
- Circulation, v.140, no.suppl.1, pp.p A12996 - p A12996
- Indexed
- SCIE
SCOPUS
- Journal Title
- Circulation
- Volume
- 140
- Number
- suppl.1
- Start Page
- p A12996
- End Page
- p A12996
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/2031
- DOI
- 10.1161/CIRC.140.SUPPL_1.12996
- ISSN
- 0009-7322
- Abstract
- Introduction: Salvaging ischemic myocardium post acute myocardial (MI) infarction has not been achieved with current treatments. Gene therapy via adeno-associated virus (AAV) offers a promising strategy since myocytes can be reprogrammed fast after MI. CCN5 is a pleiotropic target shown to rescue function and reduce fibrosis in murine models. CCN5’s mode of action is 2 fold: upregulating survival and reducing fibrosis mechanisms. Here, we attempt to validate CCN5 in a sheep MI model.
Hypothesis: CCN5 will salvage post MI myocardium and improve extracellular matrix composition through reducing levels of: TGFB signalling, myofibroblasts and collagen I deposition.
Methods: Surgical ligation of 2 arteries was performed in n=12 sheep and randomized between AAV9 null or AAV9 CCN5. 30 min after MI, 15 single AAV injections were given in the MI area, total 1 x 1013. MRI assessed function at 1 and 3 months. Assays: QPCR of genome copies, CCN5 expression, TGFB ELISA, collagen I and histology.
Results: CCN5 reduced MI size to [7±2%] F1A as compared with nulls F1B [18±2%] at 3 months. LV Ejection fraction was preserved with CCN5 [50±4%] compared to heart failure in the nulls [36±3%] F1C. End Systolic volumes were higher in the nulls [84±6mL] in to CCN5 [52±4mL] F1D. QPCR of AAV.CCN5 detected 995086 GC per 1 ug DNA or 8.1 GC/cell in the injected zones, but not distal areas. Cardiac specific CCN5 expression confirmed via confocal Fig1E and western blot. TGFB levels were significantly less in CCN5 treated samples [0.67±0.2AU] to nulls’s areas [1.6±0.3AU]. FACS cell sorting revealed significantly less myofibroblast detection range 0.2-4% for CCN5 samples versus >20% for nulls Fig1F. Collagen I (red) stain revealed significantly less formation in CCN5 [3.3±0.05AU] F1G vs high [8.2±0.07AU] in nulls F1H.
Conclusions: CCN5 preserves myocytes in the setting of MI and reduces chronic fibrosis markers. CCN5 gene therapy could be a treatment option for early stage MI or cardiac surgery indications.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF SCIENCE AND CONVERGENCE TECHNOLOGY > ERICA 의약생명과학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/2031)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.